TAZOCIN ® Piperacillin + Tazobactam

TAZOCIN ® is a drug based on Piperacillin + Tazobactam

THERAPEUTIC GROUP: General antimicrobials for systemic use - association of penicillins and beta-lactamase inhibitors

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications TAZOCIN ® Piperacillin + Tazobactam

TAZOCIN ® is indicated in the treatment of bacterial infections sustained by microorganisms sensitive to piperacillin and responsible for diseases of the lower respiratory tract, urinary tract, intra-abdominal, cutaneous and mixed pathologies.

In synergy with aminoglycosides TAZOCIN ® is indicated for the treatment of particularly severe infections sustained by Pseudomonas and other Gram negative bacteria.

Mechanism of action TAZOCIN ® Piperacillin + Tazobactam

TAZOCIN ® is a medicine with an impressive microbicidal activity guaranteed by two active ingredients, such as:

Piperacillin, a semisynthetic penicillin belonging to the ureidopenicilline category, capable of inhibiting the transpeptidation reaction of the peptidoglycan, compromising the synthesis and stability of the bacterial wall and determining the lysis of the microorganism due to osmotic shock;
Tazobactam, a penicillin derivative capable of inhibiting the activity of beta-lactamases, enzymes produced by various resistant microorganisms able to open the beta-lactam ring of the antibiotic reducing its therapeutic activity.

It is therefore evident how the association between piperacillin and tazobactam can increase the therapeutic activity of the drug, extending its action also to those resistant microorganisms for the synthesis of beta-lactamase.

From the pharmacokinetic point of view, on the other hand, the intramuscular intake of TAZOCIN ® allows both active ingredients to reach the haematic stream rapidly, maintaining a good bioavailability, distributing itself between various tissues and biological fluids in order to carry out its therapeutic activity at the end of the which may then be excreted via the kidneys.

Studies carried out and clinical efficacy

1.PIPERICILLINA / TAZOBACTAM IN THE TREATMENT OF POLMONITIS AB INGESTIS

J Infect Chemother. 2012 Mar 30.

Treatment with pipericillin and tazobactam becomes fundamental, as described in this study, for the treatment of ab ingestis pneumonia especially when complicated by overgrowing Gram bacterial infections - such as Klebsiella Pneuomoniae.

2 . BMI AND EFFECTIVENESS OF THERAPY WITH PIPERICILLIN / TAZOBACTAM

Surg Infect (Larchmt). 2012 Feb; 13 (1): 38-42. Epub 2012 Jan 4.

Interesting study to evaluate the possible effects of the body mass index on the efficacy of antibiotic therapy in abdominal infections. In this work there were no significant changes in antibiotic efficacy in patients with a body mass index greater than 30 compared to that observed in normal-weight patients.

3.IPOKALIEMIA AND METABOLIC ALCALOSIS INDUCED BY PIPERICILLINA-TAZOBACTAM

Indian J Pharmacol. 2011 Sep; 43 (5): 609-10.

Interesting case-report that reveals the appearance of hypokalemia and metabolic alkalosis in a young patient of 2 years following the intake of pipericillin-tazobactam. These studies emphasize the importance of medical supervision during antibiotic treatment.

Method of use and dosage

TAZOCIN ®

Powder and solvent for solution for injection for intramuscular use from 2 g of piperacciline and 250 mg of tazobactam for 4 ml of solution.

Intramuscular or slow intravenous administration of TAZOCIN ® should be supervised by a healthcare professional.

The doctor, after carefully assessing the patient's state of health, the presence of conditions that require special precautions and the severity of the clinical picture present, should formulate the dosage and define the recruitment scheme.

The standard dose for adults of a 2 g piperacillin injection every 12 hours may undergo significant changes at the discretion of the physician.

For this reason, medical supervision is necessary both in the definition of the dosage and in the whole therapeutic procedure.

Warnings TAZOCIN ® Piperacillin + Tazobactam

The use of TAZOCIN ® should be justified by the presence of microorganisms sensitive to pipericillin treatment, given that the indiscriminate and non-rational use of antibiotics could facilitate the appearance of drug-resistant strains capable of greatly reducing the efficacy of antibiotic therapy .

The doctor should periodically assess the patient's state of health, considering the possibility of suspending the therapy in progress following the appearance of undesirable side effects.

An adjustment of the doses used and a closer supervision is necessary in all those patients suffering from renal pathologies or in elderly subjects.

The appearance of persistent diarrhea that requires the possible integration of liquids and electrolytes should alarm the doctor, fueling the suspicion of pseudomembranous colitis.

PREGNANCY AND BREASTFEEDING

The absence of clinical trials able to characterize the safety profile on the fetus of pipercillin when taken during pregnancy, poses numerous limitations related to the use of this active ingredient during the gestational period and in the subsequent phase of breastfeeding.

For this reason TAZOCIN ® should be taken during pregnancy only in cases of real need and always under strict specialist medical supervision.

Interactions

Like other penicillins, piperacillin contained in TAZOCIN ®, could interact with other active ingredients exposing the patient to possible adverse reactions, sometimes even serious ones.

For this reason, particular attention should be paid to the simultaneous assumption of:

Vecuronium and muscle relaxants, given the increased therapeutic activity described following the simultaneous intake of piperacillin;
Allopurinol, due to the increased risk of allergic reactions;
Probenecid, responsible for the increase in blood concentrations and the hepatic and renal side effects of pipericillin;
Warfarin, due to the increased risk of bleeding;
Methotrexate, due to the high toxicity of the active ingredient.

Contraindications TAZOCIN ® Piperacillin + Tazobactam

The use of TAZOCIN ® is contraindicated in patients who are hypersensitive to penicillins and cephalosporins or their excipients and lidocaine.

Undesirable effects - Side effects

The administration of TAZOCIN ® in addition to determining the onset of possible local side effects such as redness, pain, swelling and dermatological reactions at the injection site, could contribute to the appearance of systemic reactions such as leukopenia, neutropenia, thrombocytopenia and rarely anemia, headache, insomnia, hypotension, phlebitis, diarrhea, nausea, vomiting, constipation, hypertransaminasemia, hyperbilirubinemia and fever.

Clinically relevant are also all those hypersensitivity reactions to the drug such as edema, angioedema, bronchospasm, laryngospasm, hypotension and anaphylactic shock in severe cases.